诊断新冠肺炎由轻症转重症的血浆蛋白标志物、检测试剂或试剂工具

• Format: Patent
• Language: Chinese
• Published: 08.09.2023
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

本发明涉及生物技术领域，特别涉及诊断新冠肺炎由轻症转重症的血浆蛋白标志物、检测试剂或试剂工具。该血浆蛋白标志物，包括锌-α2-糖蛋白、类粘蛋白1、类粘蛋白2、补体因子I。结果表明，这四种蛋白组合预测轻症患者转重症的受试者工作特征曲线(ROC)下面积(AUC)值为1，其预测轻症转重症的真阳性率为100％，假阳性率为0。此外，利用酶联免疫吸附(ELISA)实验发现上述四种蛋白浓度在轻症患者与重症患者血浆中均存在显著性差异，这就进一步确定了该组合预测轻症转重症的准确性。 The invention relates to the technical field of biology, in particular to a plasma protein marker, a detection reagent or a reagent tool for diagnosing severe change of new coronal virus pneumonia from mild symptoms. The plasma protein marker comprises zinc-alpha2-glycoprotein, mucoid 1, mucoid 2 and a complement factor I. Results show that the area (AUC) value under a subject working characteristic curve (ROC) for predicting the severe illness of a patient suffering from mild symptoms through combination of the four proteins is 1, the true positive rate for predicting the severe symptoms of the patient suffering from mild symptoms is 100%, and the false positive rate for predicting the severe symptoms of the patient suffering from mild symptoms is 0. In addition, enzyme-linked